'%3e%3cpath%20fill='%23ffffff'%20d='M%20226.007812%20574.207031%20C%20153%20574.207031%2093.871094%20633.339844%2093.871094%20706.34375%20C%2093.871094%20779.347656%20153%20838.476562%20226.007812%20838.476562%20C%20299.011719%20838.476562%20358.140625%20779.347656%20358.140625%20706.34375%20C%20358.140625%20633.339844%20299.011719%20574.207031%20226.007812%20574.207031%20Z%20M%20226.007812%20574.207031%20'%20fill-opacity='1'%20fill-rule='nonzero'/%3e%3c/g%3e%3cg%20clip-path='url(%23c259d1be04)'%3e%3cpath%20fill='%23ffffff'%20d='M%20936.96875%20115.105469%20C%20863.964844%20115.105469%20804.835938%20174.234375%20804.835938%20247.238281%20C%20804.835938%20320.242188%20863.964844%20379.375%20936.96875%20379.375%20C%201009.972656%20379.375%201069.105469%20320.242188%201069.105469%20247.238281%20C%201069.105469%20174.234375%201009.972656%20115.105469%20936.96875%20115.105469%20Z%20M%20936.96875%20115.105469%20'%20fill-opacity='1'%20fill-rule='nonzero'/%3e%3c/g%3e%3cg%20clip-path='url(%23352427e82d)'%3e%3cpath%20fill='%23ffffff'%20d='M%201189.242188%201157.730469%20C%201116.238281%201157.730469%201057.105469%201216.863281%201057.105469%201289.867188%20C%201057.105469%201362.871094%201116.238281%201422%201189.242188%201422%20C%201262.246094%201422%201321.375%201362.871094%201321.375%201289.867188%20C%201321.375%201216.863281%201262.246094%201157.730469%201189.242188%201157.730469%20Z%20M%201189.242188%201157.730469%20'%20fill-opacity='1'%20fill-rule='nonzero'/%3e%3c/g%3e%3cg%20clip-path='url(%23f67a3a7a20)'%3e%3cpath%20fill='%23ffffff'%20d='M%20756.414062%20511.328125%20C%20622.160156%20511.328125%20513.425781%20620.066406%20513.425781%20754.316406%20C%20513.425781%20888.566406%20622.160156%20997.304688%20756.414062%20997.304688%20C%20890.664062%20997.304688%20999.402344%20888.566406%20999.402344%20754.316406%20C%20999.402344%20620.066406%20890.664062%20511.328125%20756.414062%20511.328125%20Z%20M%20756.414062%20511.328125%20'%20fill-opacity='1'%20fill-rule='nonzero'/%3e%3c/g%3e%3cpath%20stroke-linecap='butt'%20transform='matrix(0.75,%200,%200,%200.75,%20226.007095,%20719.067518)'%20fill='none'%20stroke-linejoin='miter'%20d='M%200.000957089%2014.998519%20L%20640.001012%2014.998519%20'%20stroke='%23ffffff'%20stroke-width='30'%20stroke-opacity='1'%20stroke-miterlimit='4'/%3e%3cpath%20stroke-linecap='butt'%20transform='matrix(0.220142,%20-0.716964,%200.716964,%200.220142,%20822.082523,%20526.918183)'%20fill='none'%20stroke-linejoin='miter'%20d='M%200.00159185%2014.998056%20L%20248.679965%2015.000052%20'%20stroke='%23ffffff'%20stroke-width='30'%20stroke-opacity='1'%20stroke-miterlimit='4'/%3e%3cpath%20stroke-linecap='butt'%20transform='matrix(-0.501722,%20-0.557472,%200.557472,%20-0.501722,%201129.821968,%201216.754515)'%20fill='none'%20stroke-linejoin='miter'%20d='M%20-0.00137282%2014.997961%20L%20608.594779%2015.002501%20'%20stroke='%23ffffff'%20stroke-width='30'%20stroke-opacity='1'%20stroke-miterlimit='4'/%3e%3c/svg%3e)
PharmAla Biotech
(01) About PharmAla
We are a Canadian biotechnology company dedicated to the domestic research & development and sourcing of clinical-grade LaNeo™ MDMA and novel MDXX compounds in service to the scientific research community and commercial use in select jurisdictions.
Past Clients
(02) Discover our difference
PharmAla is licensed to sell MDMA and Psilocybin under Health Canada's Controlled Drugs and Substances Dealer's License
Pharmaceutical Standards
Every batch is manufactured to GMP standards and certificate-of-analysis verified, giving research teams confidence in the consistency and purity required for regulated clinical trials.
Novel Compound Pipeline
Our MDXX program develops the next generation of empathogen analogues — proprietary new chemical entities engineered for improved therapeutic windows and patient experience.
Global Research Network
From Canada to Australia, from EU regulators to private clinics, we partner with research programs on four continents — anticipating regulatory trends and unlocking patient access.
(05) Investors
Why invest in PharmAla Biotech?
The Psychedelics market in the US is growing with a CAGR of 16% in the forecast period of 2020 to 2027 and is expected to reach US$ 6.9B by 2027 from US$ 2.1B in 2019. MDMA is the first "psychedelic" molecule likely to be granted regulatory approval as a medicine in the US, having already completed two Phase III trials, it is currently under consideration for approval by the FDA.
See our most recent company presentation to learn more about investing in PharmAla Biotech.
Download PresentationCurrently, there is a global shortage of MDMA to sustain critical research. While MDMA is an off-patent molecule, the process development and regulatory burden for the manufacturing of a controlled substance have significantly narrowed the number of manufacturers. PharmAla Biotech, in concert with our manufacturing partners, is currently the only supplier of MDMA for human use in Canada manufactured under Good Manufacturing Practice guidelines.
(03) How we're different
A regulatory-first approach to improving the molecule itself — not just proving what it can do.
Regulators look at drugs through two lenses: efficacy, and safety. While many companies are working to prove the efficacy of LaNeo™ MDMA in treating various conditions, PharmAla is one of only a small number of companies working to improve the molecule's safety. We selected this approach because PharmAla is a "regulatory-first" organization: we know there is no pathway to drug approval without trust from regulators.
PharmAla Biotech has developed the first legal commercial value chain in North America for clinical-grade GMP LaNeo™ MDMA products. We are researching novel formulation methods and delivery pathways to ensure that the LaNeo™ MDMA developed by the company can be delivered by researchers and clinicians with the greatest safety, while reducing cost.
Stay in the loop.
Join our email list to have the latest news and developments sent directly to your inbox. You can unsubscribe any time.